Miconazole in cryptococcosis and systemic candidiasis: A word of caution

J. E. Bennett, J. S. Remington

Research output: Contribution to journalArticle

Abstract

In the search for new, effective, and less toxic drugs for treatment of life-threatening fungal infections, it is not surprising that release by the FDA of a drug purported to have these attributes would be welcomed by physicians who for years have been frustrated with the problems associated with presently available antifungal drugs. Antifungal drugs are not, like most antibacterial antibiotics, joining a legion of similar drugs that are frequently of equal or even greater efficacy and that often have similar or even fewer side effects; indeed, any new agent for treating cryptococcal meningitis and systemic candidiasis enters an arena in which there are essentially only two other drugs, one severely limited by its narrow spectrum (flucytosine) and the other by its toxicity (amphotericin B). The normal tendency of a physician to try intravenous miconazole as an alternative to these two older drugs must be balanced by the knowledge that the efficacy of this new drug for cryptococcosis and candidiasis has not been established.

Original languageEnglish (US)
Pages (from-to)708-709
Number of pages2
JournalAnnals of Internal Medicine
Volume94
Issue number5
StatePublished - 1981
Externally publishedYes

Fingerprint

Miconazole
Cryptococcosis
Pharmaceutical Preparations
Cryptococcal Meningitis
Physicians
Flucytosine
Systemic candidiasis
Mycoses
Candidiasis
Poisons
Amphotericin B
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Miconazole in cryptococcosis and systemic candidiasis : A word of caution. / Bennett, J. E.; Remington, J. S.

In: Annals of Internal Medicine, Vol. 94, No. 5, 1981, p. 708-709.

Research output: Contribution to journalArticle

Bennett, JE & Remington, JS 1981, 'Miconazole in cryptococcosis and systemic candidiasis: A word of caution', Annals of Internal Medicine, vol. 94, no. 5, pp. 708-709.
Bennett, J. E. ; Remington, J. S. / Miconazole in cryptococcosis and systemic candidiasis : A word of caution. In: Annals of Internal Medicine. 1981 ; Vol. 94, No. 5. pp. 708-709.
@article{fa91641edb6b477f984d36b57b0b8c43,
title = "Miconazole in cryptococcosis and systemic candidiasis: A word of caution",
abstract = "In the search for new, effective, and less toxic drugs for treatment of life-threatening fungal infections, it is not surprising that release by the FDA of a drug purported to have these attributes would be welcomed by physicians who for years have been frustrated with the problems associated with presently available antifungal drugs. Antifungal drugs are not, like most antibacterial antibiotics, joining a legion of similar drugs that are frequently of equal or even greater efficacy and that often have similar or even fewer side effects; indeed, any new agent for treating cryptococcal meningitis and systemic candidiasis enters an arena in which there are essentially only two other drugs, one severely limited by its narrow spectrum (flucytosine) and the other by its toxicity (amphotericin B). The normal tendency of a physician to try intravenous miconazole as an alternative to these two older drugs must be balanced by the knowledge that the efficacy of this new drug for cryptococcosis and candidiasis has not been established.",
author = "Bennett, {J. E.} and Remington, {J. S.}",
year = "1981",
language = "English (US)",
volume = "94",
pages = "708--709",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "5",

}

TY - JOUR

T1 - Miconazole in cryptococcosis and systemic candidiasis

T2 - A word of caution

AU - Bennett, J. E.

AU - Remington, J. S.

PY - 1981

Y1 - 1981

N2 - In the search for new, effective, and less toxic drugs for treatment of life-threatening fungal infections, it is not surprising that release by the FDA of a drug purported to have these attributes would be welcomed by physicians who for years have been frustrated with the problems associated with presently available antifungal drugs. Antifungal drugs are not, like most antibacterial antibiotics, joining a legion of similar drugs that are frequently of equal or even greater efficacy and that often have similar or even fewer side effects; indeed, any new agent for treating cryptococcal meningitis and systemic candidiasis enters an arena in which there are essentially only two other drugs, one severely limited by its narrow spectrum (flucytosine) and the other by its toxicity (amphotericin B). The normal tendency of a physician to try intravenous miconazole as an alternative to these two older drugs must be balanced by the knowledge that the efficacy of this new drug for cryptococcosis and candidiasis has not been established.

AB - In the search for new, effective, and less toxic drugs for treatment of life-threatening fungal infections, it is not surprising that release by the FDA of a drug purported to have these attributes would be welcomed by physicians who for years have been frustrated with the problems associated with presently available antifungal drugs. Antifungal drugs are not, like most antibacterial antibiotics, joining a legion of similar drugs that are frequently of equal or even greater efficacy and that often have similar or even fewer side effects; indeed, any new agent for treating cryptococcal meningitis and systemic candidiasis enters an arena in which there are essentially only two other drugs, one severely limited by its narrow spectrum (flucytosine) and the other by its toxicity (amphotericin B). The normal tendency of a physician to try intravenous miconazole as an alternative to these two older drugs must be balanced by the knowledge that the efficacy of this new drug for cryptococcosis and candidiasis has not been established.

UR - http://www.scopus.com/inward/record.url?scp=0019427473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019427473&partnerID=8YFLogxK

M3 - Article

C2 - 7235405

AN - SCOPUS:0019427473

VL - 94

SP - 708

EP - 709

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 5

ER -